Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status

Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci; on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Konrad H. Stopsack
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Konrad H. Stopsack
  • For correspondence: stopsack@mskcc.org
Amparo G. Gonzalez-Feliciano
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel F. Peisch
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary K. Downer
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riley A. Gage
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Finn
4Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
5Department of Pathology, Trinity College Dublin, Dublin, Ireland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen Finn
Rosina T. Lis
6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca E. Graff
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
7Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rebecca E. Graff
Andreas Pettersson
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
8Department of Medicine, Clinical Epidemiology Unit, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire H. Pernar
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Loda
4Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip W. Kantoff
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas U. Ahearn
9National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorelei A. Mucci
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-18-0510 Published October 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1.

    Characteristics of participants of the HPFS by aspirin use at baseline, standardized to the age distribution of the study population

    Baseline characteristics, 1986Nonusers of aspirinCurrent users of aspirin
    N34,84814,547
    Frequency of aspirin use, mean (SD; d/mo)0.08.6 (0.0)a
    Age, mean (SD; y)b53.7 (9.7)56.5 (9.7)
    BMI, mean (SD; kg/m2)25.5 (3.3)25.7 (3.5)
    Family history of prostate cancer12.0%11.8%
    Smoking status
     Never smoker45.7%41.8%
     Past smoker39.6%47.3%
     Current smoker9.3%10.4%
     Missing5.4%0.5%
    Total physical activity, mean (SD; METS-h/wk)18.8 (26.5)18.6 (26.1)
    Diabetes diagnosis3.0%3.6%
    Cumulative incidence, by 2009
     Prostate cancer diagnosis12.5%12.7%
     Prostate cancer death1.3%1.1%
     Overall mortality27.7%30.8%
    • Abbreviations: BMI, body mass index; METS, metabolic equivalent tasks.

    • ↵aThis increased to 26.3 days/month (mean; SD, 4.6) among current aspirin users in 2010.

    • ↵bNot adjusted for age.

  • Table 2.

    ERG-positive and ERG-negative incident prostate cancer by aspirin use (fully adjusted modela)

    No. of casesHR (95% CI)
    ERG-positiveERG-negative
    Total439473ERG-positiveERG-negative
    Categories of use
     Never user1471381 (ref)1 (ref)
     Past user1071141.02 (0.79–1.31)1.04 (0.82–1.33)
     Current user1852211.03 (0.83–1.28)1.11 (0.89–1.37)
     Pheterogeneity = 0.88
    Current use
     Never/past user2542521 (ref)1 (ref)
     Current user1852211.02 (0.85–1.23)1.09 (0.91–1.30)
     Pheterogeneity = 0.63
    Ever use
     Never user1471381 (ref)1 (ref)
     Ever user2923351.03 (0.84–1.25)1.08 (0.89–1.33)
     Pheterogeneity = 0.69
    Duration of use since baseline
     Non-aspirin user1471381 (ref)1 (ref)
     Aspirin use <5 years1341491.00 (0.79–1.26)1.17 (0.94–1.46)
     Aspirin use 5–<10 years90921.11 (0.85–1.44)0.98 (0.76–1.28)
     Aspirin use 10 years+68940.96 (0.71–1.30)1.03 (0.77–1.37)
     Pheterogeneity = 0.48
     Per year of use4394731.00 (1.00–1.00)1.00 (1.00–1.00)
     Pheterogeneity = 0.62
    Frequency of use
     Aspirin use <2 d/wk (never/past user)2542521 (ref)1 (ref)
     Aspirin use 2–<6 d/wk72810.94 (0.73–1.21)1.05 (0.83–1.33)
     Aspirin use 6+ d/wk1131401.09 (0.87–1.37)1.12 (0.90–1.39)
     Pheterogeneity = 0.82
     Per d/wk of use4394731.02 (0.98–1.05)1.01 (0.98–1.05)
     Pheterogeneity = 0.93
    • Abbreviation: ref, reference category.

    • ↵aAdjusted for age, calendar time, race (Caucasian, other), family history of prostate cancer in father or brother (yes, no), height (≤68, >68–70, >70–72, >72 inches), body mass index (<21, 21–<25, 25–<30, 30+ kg/m2), body mass index at age 21 years (<20, 21–<25, 25–<30, 30+ kg/m2), physical activity (quintiles of metabolic equivalents-hours/week), smoking (never, former/quit >10 years ago, former/quit ≤10 years ago, current), history of diabetes (yes, no), time-varying current statin use (yes, no), PSA testing in the 2 years prior to the questionnaire date (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening), and PSA testing in >50% of possible time periods (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening).

PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 27 (10)
October 2018
Volume 27, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Cancer Epidemiol Biomarkers Prev October 1 2018 (27) (10) 1231-1233; DOI: 10.1158/1055-9965.EPI-18-0510

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Cancer Epidemiol Biomarkers Prev October 1 2018 (27) (10) 1231-1233; DOI: 10.1158/1055-9965.EPI-18-0510
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Diet Quality and Ovarian Cancer Survival
  • PDE5 inhibitors use and precursors of colorectal cancer
  • Association between serum iron biomarkers and breast cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement